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      Therapeutic drug monitoring (TDM) is the experimental measurement of a drug concentration that leads to 
determination of drug dosage, to keep plasma/blood drug concentrations within a targeted therapeutic window. 
Back to the 1970s, drug monitoring was initiated to evaluate the incidence of toxicity to drugs such as digoxin, 
phenytoin, lithium, and theophylline. Drug monitoring is used to evaluate the efficacy, compliance, drug-drug 
interactions, and also to prevent drug toxicity. When the drug is being used as prophylaxis, it is impossible to 
monitor a response. Thus, the physician can select a dosage that will produce a certain target plasma 
concentration. For example, lithium in preventing manic-depressive, phenytoin in preventing seizures after 
neurosurgery or trauma, and cyclosporine in preventing transplant rejection. In some cases, plasma concentration 
measurements obtained during treatment enable the physician to avoid toxic plasma concentrations. For example, 
digoxin toxicity may mimic certain symptoms of heart disease, and measuring the plasma concentration in cases 
in which toxicity is suspected may be helpful in confirming the diagnosis. Similarly, nephrotoxicity of 
aminoglycoside antibiotics is difficult to distinguish clinically from that caused by a severe infection. Other 
important aspects of modern TDM is to individualize dosing, by understanding the molecular mechanisms 
involved in drug effects. Genotyping is used to determine the appropriate dosage for each person based on 
polymorphisms in involved proteins. The combination of TDM and the genotyping of drug metabolizing 
enzymes or transporters provide a more precise method to predict drug target levels. Today, TDM is used along 
with genotyping to predict the required therapeutic dose of certain drugs. Genetic difference in cytochrome P450 
enzymes causes variable metabolism capacities among individuals. Understanding the polymorphisms of the 
genes encoding metabolizing enzymes or target molecules could guide the physician to suggest the appropriate 
dosing required for each individual.  
TDM is routinely used in four areas of pharmacotherapy: immunosuppression, epilepsy, infectious diseases and 
psychiatry. Both chromatographic and immunochemistry techniques have been used for TDM services. The 
recent development in chromatography, which combines liquid chromatography and mass spectrometry (LC-MS) 
is the preferred technique for assaying chemical compounds in body fluids. The LC-tandem MS (LC-MS/MS) 
technique provides even more selectivity than single MS detection methods. In the future, LC-MS/MS will likely 
be replaced with conventional TDM services because it enables us to simultaneously analyze several agents in 
biological fluids instead of just one specific compound. Moreover, the high-resolution MS can be used in 
metabolic studies and in studies on biomarkers of genetic polymorphisms.  
Another novel application of TDM is the use of new biological matrices such as “dried blood spots” in neonatal 
screening and “oral fluid” for testing drugs of abuse. The advantage of dried blood spot is its simple blood 
collection method without the involvement of professional personnel. However, for dried blood spot, it is still 
necessary to standardize the sampling regarding the exact blood volume. In oral fluid, one possible advantage 
might be that the oral fluid sample better reflects the un-bound fraction of the drugs in blood.  
There is strong link between TDM service and researches. Properly stored drug concentration data and associated 
clinical information can be used as a database for pharmacological research. The routine TDM data, if available 
in sufficient case number, could be used for research purposes. The computerized data recording made data 
extraction easier than the past. Moreover, utilizing pharmacokinetic-based mathematical models for the 
evaluation of drug concentrations would more precisely predict the effect of suggested dose adjustment. 
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